RxDoctor Payments Data

Fadi El-Ahdab, MD

Interventional Cardiology · Charlotte, NCNPI 1932316163

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Boston Scientific at 28.4% of the total. Reporting peaked in 2024 at $503 and has fallen 51.6% since, to $244 in 2025. That places this record below the midpoint for interventional cardiology clinicians in NC, where the typical reported total is $5,390.

$1,372in general payments, 2019–2025

Across 60 payments — averaging $22.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$390
  • Edwards Lifesciences$324
  • Medtronic$162
  • Abiomed$161
  • Novartis$53
  • Penumbra, Inc.$39
  • plus $245 from 10 others
$14,697in research payments, 2019–2025

Across 21 payments — averaging $699.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$15K

What the payments were for

  • Food & beverage$1,372100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,372 in reported general payments places this provider in the 15th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina →

Medicare billing

Part B allowed, 2024
$145,546
Medicare patients
894
Services billed
1,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$91,168
XareltoRivaroxaban20$21,870
Repatha SureclickEvolocumab18$17,990
Prasugrel Hcl21$975
Amlodipine Besylate184$895
Atorvastatin Calcium110$856
ClopidogrelClopidogrel Bisulfate47$713
Metoprolol Succinate41$542
Carvedilol82$503
Famotidine33$497
Hydralazine Hcl38$439
Losartan Potassium54$435
Lisinopril50$402
Isosorbide Mononitrate ErIsosorbide Mononitrate39$380
Furosemide124$312

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Charlotte

See the full list for North Carolina →

Where these figures come from

Is this you, or does something look wrong? →